Infant Hospitalizations and Fatalities Averted by the Maternal Pertussis Vaccination Program in England, 2012-2017: Post-implementation Economic Evaluation.
Sandmann, F
; Jit, M; Andrews, N; Buckley, HL; Campbell, H; Ribeiro, S; Sile, B; Stowe, J; Tessier, E; Ramsay, M; +2 more...Choi, YH; Amirthalingam, G and
(2020)
Infant Hospitalizations and Fatalities Averted by the Maternal Pertussis Vaccination Program in England, 2012-2017: Post-implementation Economic Evaluation.
CLINICAL INFECTIOUS DISEASES, 71 (8).
pp. 1984-1987.
ISSN 1058-4838
DOI: 10.1093/cid/ciaa165
; Jit, M; Andrews, N; Buckley, HL; Campbell, H; Ribeiro, S; Sile, B; Stowe, J; Tessier, E; Ramsay, M; +2 more...Choi, YH; Amirthalingam, G and
(2020)
Infant Hospitalizations and Fatalities Averted by the Maternal Pertussis Vaccination Program in England, 2012-2017: Post-implementation Economic Evaluation.
CLINICAL INFECTIOUS DISEASES, 71 (8).
pp. 1984-1987.
ISSN 1058-4838
DOI: 10.1093/cid/ciaa165
In October 2012, a maternal pertussis vaccination program was implemented in England following an increased incidence and mortality in infants. We evaluated the cost-effectiveness of the program by comparing pertussis-related infant hospitalizations and deaths in 2012-2017 with nonvaccination scenarios. Despite considerable uncertainties, findings support the cost-effectiveness of the program.
-
picture_as_pdf - ciaa165(1).pdf
-
subject - Published Version
-
copyright - Available under Copyright the publishers
Downloads